Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Other Non-Current Liabilities (2019 - 2025)

BridgeBio Pharma's Other Non-Current Liabilities history spans 7 years, with the latest figure at $545000.0 for Q2 2025.

  • For Q2 2025, Other Non-Current Liabilities rose 12.37% year-over-year to $545000.0; the TTM value through Jun 2025 reached $545000.0, up 12.37%, while the annual FY2024 figure was $286000.0, 94.92% down from the prior year.
  • Other Non-Current Liabilities for Q2 2025 was $545000.0 at BridgeBio Pharma, up from $352000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $28.6 million in Q2 2022 and bottomed at $286000.0 in Q4 2024.
  • The 5-year median for Other Non-Current Liabilities is $12.5 million (2021), against an average of $13.1 million.
  • The largest annual shift saw Other Non-Current Liabilities soared 315.16% in 2021 before it crashed 96.8% in 2024.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $22.1 million in 2021, then grew by 20.73% to $26.6 million in 2022, then tumbled by 78.85% to $5.6 million in 2023, then plummeted by 94.92% to $286000.0 in 2024, then soared by 90.56% to $545000.0 in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Other Non-Current Liabilities are $545000.0 (Q2 2025), $352000.0 (Q1 2025), and $286000.0 (Q4 2024).